The inhibitors of the vascular endothelial growth factor (VEGF) signalling pathway (bevacizumab, sorafenib, sunitinib, and pazopanib) act via multiple mechanisms similar to the pathophysiology of preeclampsia, influencing nitric oxide production in the arterial wall, and their effect on blood pressure is considered as a surrogate for anti-cancer treatment efficacy [4]. This evidence concerns the gene VEGFA and cancer.